SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Isoflupredone

Item No. 35376

CAS Registry No.:	338-95-4
Formal Name:	9-fluoro-11β,17,21-trihydroxy-pregna-1,4-diene-3,20-dione
Synonyms:	Δ-Fluorocortisone, 9α-Fluoroprednisolone, NSC 12174
MF:	$C_{21}H_{27}FO_5$
FW:	378.4
Purity:	≥95%
UV/Vis.:	λ_{max}: 239 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Isoflupredone is supplied as a solid. A stock solution may be made by dissolving the isoflupredone in the solvent of choice, which should be purged with an inert gas. Isoflupredone is slightly soluble in ethyl acetate and DMSO.

Description

Isoflupredone is an agonist of glucocorticoid and mineralocorticoid receptors (EC_{50}s = 0.877 and 0.007 nM, respectively, in transactivation assays).[1] It inhibits LPS-induced nitric oxide (NO) production in RAW 264.7 macrophages (IC_{50} = 25.5 nM).[2] Topical application of a solution containing isoflupredone inhibits croton oil-induced ear edema in rats (ED_{50} = 51.9 nM). Isoflupredone (0.6 mg/day) increases mean arterial pressure (MAP) and decreases the levels of potassium and sodium in the plasma and urine, respectively, in sheep.[3] It reduces tumor levels of uridine incorporation into 18S and 28S rRNA in a P1798 murine lymphoma model when administered at a dose of 25 mg/kg.[4]

References

1. Grossmann, C., Scholz, T., Rochel, M., *et al.* Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: A comparison of their glucocorticoid and mineralocorticoid properties. *Eur. J. Endocrinol.* **151(3)**, 397-406 (2004).
2. Park, K.-K., Ko, D.-H., You, Z., *et al.* Synthesis and pharmacological evaluations of new steroidal anti-inflammatory antedrugs: 9α-Fluoro-11β,17α,21-trihydroxy-3,20-dioxo-pregna-1,4-diene-16α-carboxylate (FP16CM) and its derivatives. *Steroids* **71(1)**, 83-89 (2006).
3. Coghlan, J.P., Denton, D.A., Mills, E.H., *et al.* Steroid antagonism of the 'hypertensinogenic' activity of 9α-fluoroprednisolone. *Life Sci.* **35(26)**, 2609-2612 (1984).
4. Stevens, J., Mashburn, L.T., and Hollander, V.P. Effect of 9α-fluoroprednisolone and L-asparaginase on uridine incorporation into ribosomal RNA of P1798 lymphosarcoma. *Biochim. Biophys. Acta* **186(2)**, 332-339 (1969).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM